138 related articles for article (PubMed ID: 1550085)
1. Fotemustine and DTIC combination in patients with disseminated malignant melanoma.
Merimsky O; Inbar M; Chaitchik S
Am J Clin Oncol; 1992 Feb; 15(1):84-6. PubMed ID: 1550085
[TBL] [Abstract][Full Text] [Related]
2. Combination chemotherapy of dacarbazine and fotemustine in disseminated malignant melanoma. Experience of the French Study Group.
Avril MF; Bonneterre J; Delaunay M; Grosshans E; Fumoleua P; Israel L; Bugat R; Namer M; Cupissol D; Kerbrat P
Cancer Chemother Pharmacol; 1990; 27(2):81-4. PubMed ID: 2249337
[TBL] [Abstract][Full Text] [Related]
3. Combined treatment with dacarbazine, cisplatin, fotemustine and tamoxifen in metastatic malignant melanoma.
Richard MA; Grob JJ; Zarrour H; Bassères N; Bizzari JP; Gérard B; Bonerandi JJ
Melanoma Res; 1998 Apr; 8(2):170-4. PubMed ID: 9610872
[TBL] [Abstract][Full Text] [Related]
4. Fotemustine--an advance in the treatment of metastatic malignant melanoma.
Merimsky O; Inbar M; Gerard B; Chaitchik S
Melanoma Res; 1992 Dec; 2(5-6):401-6. PubMed ID: 1292787
[TBL] [Abstract][Full Text] [Related]
5. Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma.
Lee SM; Margison GP; Woodcock AA; Thatcher N
Br J Cancer; 1993 Jun; 67(6):1356-60. PubMed ID: 8512821
[TBL] [Abstract][Full Text] [Related]
6. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.
Avril MF; Aamdal S; Grob JJ; Hauschild A; Mohr P; Bonerandi JJ; Weichenthal M; Neuber K; Bieber T; Gilde K; Guillem Porta V; Fra J; Bonneterre J; Saïag P; Kamanabrou D; Pehamberger H; Sufliarsky J; Gonzalez Larriba JL; Scherrer A; Menu Y
J Clin Oncol; 2004 Mar; 22(6):1118-25. PubMed ID: 15020614
[TBL] [Abstract][Full Text] [Related]
7. Fotemustine, dacarbazine, vindesine combination chemotherapy in advanced malignant melanoma: a phase II study of 43 patients.
Rixe O; Borel C; Paraiso D; Benhammouda A; Petit T; Antoine E; Bizzari JP; Auclerc G; Soubrane C; Weil M
Melanoma Res; 1995 Dec; 5(6):419-24. PubMed ID: 8589616
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of the sequential administration of dacarbazine and fotemustine in the treatment of cerebral metastases from malignant melanoma.
Chang J; Atkinson H; A'Hern R; Lorentzos A; Gore ME
Eur J Cancer; 1994; 30A(14):2093-5. PubMed ID: 7857710
[TBL] [Abstract][Full Text] [Related]
9. Fotemustine: an overview of its clinical activity in disseminated malignant melanoma.
Khayat D; Avril MF; Gerard B; Bertrand P; Bizzari JP; Cour V
Melanoma Res; 1992 Sep; 2(3):147-51. PubMed ID: 1450667
[TBL] [Abstract][Full Text] [Related]
10. Fotemustine and interferon alpha2b in metastatic malignant melanoma.
Weichenthal M; Mohr P; Stephan U; Altenhoff J; Kowalzick L; Marseille A; Sarkany M; Hossfeld DK; Breitbart EW
J Cancer Res Clin Oncol; 1998 Jan; 124(1):55-9. PubMed ID: 9498836
[TBL] [Abstract][Full Text] [Related]
11. Treatment of metastatic malignant melanoma with dacarbazine plus fotemustine.
Seeber A; Binder M; Steiner A; Wolff K; Pehamberger H
Eur J Cancer; 1998 Dec; 34(13):2129-31. PubMed ID: 10070323
[TBL] [Abstract][Full Text] [Related]
12. Fotemustine plus dacarbazine for malignant melanoma.
Avril MF; Bonneterre J; Cupissol D; Grob JJ; Kalis B; Fumoleau P; Kerbrat P; Israel L; Fargeot P; Lambert D
Eur J Cancer; 1992; 28A(11):1807-11. PubMed ID: 1389514
[TBL] [Abstract][Full Text] [Related]
13. Management of cerebral metastases from malignant melanoma: results of a combined, simultaneous treatment with fotemustine and irradiation.
Ulrich J; Gademann G; Gollnick H
J Neurooncol; 1999 Jun; 43(2):173-8. PubMed ID: 10533730
[TBL] [Abstract][Full Text] [Related]
14. Temozolomide in combination with fotemustine in patients with metastatic melanoma.
Tas F; Camlica H; Topuz E
Cancer Chemother Pharmacol; 2008 Jul; 62(2):293-8. PubMed ID: 17909803
[TBL] [Abstract][Full Text] [Related]
15. Long-term complete remissions in patients with disseminated melanoma treated by fotemustine and dacarbazine.
Oliver V; Aliaga A; Lopez Lopez JJ; Perez E; Ponchon A; Bizzari JP; Cour V
Eur J Cancer; 1993; 29A(2):287. PubMed ID: 8422299
[No Abstract] [Full Text] [Related]
16. Activity and unexpected lung toxicity of the sequential administration of two alkylating agents--dacarbazine and fotemustine--in patients with melanoma.
Gerard B; Aamdal S; Lee SM; Leyvraz S; Lucas C; D'Incalci M; Bizzari JP
Eur J Cancer; 1993; 29A(5):711-9. PubMed ID: 8471329
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group.
Daponte A; Ascierto PA; Gravina A; Melucci MT; Palmieri G; Comella P; Cellerino R; DeLena M; Marini G; Comella G;
Cancer; 2000 Dec; 89(12):2630-6. PubMed ID: 11135225
[TBL] [Abstract][Full Text] [Related]
18. Fotemustine and dacarbazine plus recombinant interferon alpha 2a in thetreatment of advanced melanoma.
Comella P; Daponte A; Casaretti R; Ionna F; Fiore F; Presutti F; Frasci G; Caponigro F; Gravina A; Parziale AP; Mozzillo N; Comella G
Eur J Cancer; 1997 Jul; 33(8):1326-9. PubMed ID: 9301463
[TBL] [Abstract][Full Text] [Related]
19. [Combination of fotemustine-dacarbazine and interferon alpha in the treatment of metastatic malignant melanoma].
Célérier P; Dreno B; Bureau B; Litoux P
Ann Dermatol Venereol; 1993; 120(6-7):437-40. PubMed ID: 8279787
[TBL] [Abstract][Full Text] [Related]
20. Fotemustine plus dacarbazine in advanced stage III malignant melanoma.
Binder M; Winkler A; Dorffner R; Glebowski E; Wolff K; Pehamberger H
Eur J Cancer; 1992; 28A(11):1814-6. PubMed ID: 1389516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
